Antonio Lo Bello

Comparing real-world continuous clinical remission rates of anti-tumor necrosis factor, vedolizumab, ustekinumab, tofacitinib, and upadacitinib in ulcerative colitis

Abstract Background Multiple advanced therapies are available for moderate-to-severe ulcerative colitis (UC), but comparative efficacy data are limited. We compared the 1-year efficacy and safety of 7 therapies: the anti-tumor necrosis factor agents infliximab, adalimumab, and go...